Anhui Huangshan Capsule's (SZSE:002817) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Anhui Huangshan Capsule's (SZSE:002817) Sluggish Earnings Might Be Just The Beginning Of Its Problems
A lackluster earnings announcement from Anhui Huangshan Capsule Co., Ltd. (SZSE:002817) last week didn't sink the stock price. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.
上周,安徽黄山胶囊有限公司(SZSE:002817)发布了一份不太理想的盈利公告,但股价并没有下跌。我们的分析表明,除了利润数据不尽理想之外,投资者还应注意一些其他潜在的数字弱点。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
Importantly, our data indicates that Anhui Huangshan Capsule's profit received a boost of CN¥4.8m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. If Anhui Huangshan Capsule doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
重要的是,我们的数据显示,过去一年中,安徽黄山胶囊的利润在异常项目中增加了480万元。虽然高利润总是令人高兴的,但异常项目的大力贡献有时会降低我们的热情。当我们分析全球大多数上市公司时,我们发现重要的异常项目通常不会重复出现。这并不奇怪,因为名字已经说明了问题。如果安徽黄山胶囊没能再次贡献这部份利润,那么其他条件不变的情况下,我们预计它的利润在本年度会下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Anhui Huangshan Capsule.
注:我们始终建议投资者检查资产负债表的实力。点击这里查看我们对安徽黄山胶囊资产负债表的分析。
Our Take On Anhui Huangshan Capsule's Profit Performance
我们对安徽黄山胶囊的利润表现的观点
We'd posit that Anhui Huangshan Capsule's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Anhui Huangshan Capsule's true underlying earnings power is actually less than its statutory profit. But at least holders can take some solace from the 8.4% per annum growth in EPS for the last three. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Every company has risks, and we've spotted 1 warning sign for Anhui Huangshan Capsule you should know about.
我们认为,由于存在大笔的不寻常项目,安徽黄山胶囊的法定收益并不是一个干净的指标,无法准确反映其持续的盈利能力。因此,我们认为安徽黄山胶囊的真实基本盈利能力可能低于其法定利润。但至少持有者们可以从过去三年每股收益年均增长8.4%中获得一些慰藉。最重要的是,如果您想正确了解这家公司,必须考虑到不仅仅是上述因素。请记住,当分析一只股票时,注意到其中涉及的风险是值得注意的。每家公司都有风险,我们已经发现了安徽黄山胶囊的1个警示信号,您需要知道。
This note has only looked at a single factor that sheds light on the nature of Anhui Huangshan Capsule's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
这份报告只关注了安徽黄山胶囊利润性质的一个因素。但如果您能够专注于细枝末节,就能发现更多的信息。有些人认为,资产回报率高是一家优质企业的一个好迹象。因此,您可能希望查看这个免费的企业收益率高的收藏,或者这个高内部持股的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。